New treatment options for acute rhinosinusitis according to EPOS 2020.

Otolaryngol Pol

Department of Otolaryngology and Laryngological Oncology with Clinical Department of Craniomaxillofacial Surgery, Military Medical Institute, Warsaw, Poland.

Published: December 2021

Acute rhinosinusitis (ARS) is a very common condition and mostly of viral origin. About 0.5-2% of the viral ARS are complicated by a bacterial infection. Due to viral etiology and inflammatory mechanisms of rhinitis and rhinosinusitis, symptomatic treatment including phytotherapy have been used for their treatment for decades. Scientific societies and expert groups recommend the use of herbal medicines in acute viral and acute post-viral rhinosinusitis. In 2021, Polish patients gained access to a new therapeutic option for acute sinusitis in the form of a drug containing a distillate of a mixture of rectified essential oils of eucalyptus, sweet orange, myrtle and lemon common.

Download full-text PDF

Source
http://dx.doi.org/10.5604/01.3001.0015.7094DOI Listing

Publication Analysis

Top Keywords

acute rhinosinusitis
8
acute
5
treatment options
4
options acute
4
rhinosinusitis
4
rhinosinusitis epos
4
epos 2020
4
2020 acute
4
rhinosinusitis ars
4
ars common
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!